Search

everythinglearnresearchcommunity

for

Search:↓

Low-dose oral minoxidil is safe for hair loss, with no link between side effects and patient demographics.

CDK4/6 inhibitors may cause hair loss in breast cancer patients.

Poliosis is common in severe alopecia areata but doesn't significantly affect overall prognosis.

Women with lichen planopilaris and frontal fibrosing alopecia often have other health issues like hypothyroidism and lupus.

Black patients with discoid lupus erythematosus have more severe skin damage and higher chances of dyspigmentation, scalp, and ear involvement.

Topical dapsone gel reduced flare-ups in folliculitis decalvans without side effects.

Most transgender adolescents continued hormone treatment, with few stopping due to reasons other than returning to their birth gender.

Early treatment of fibrosing alopecia in a pattern distribution may improve outcomes.

People who get alopecia areata after age 50 usually have mild symptoms, high chances of hair regrowth, and often have other health conditions.

Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.

Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.

Degenerative changes in the lower cervical spine are common in patients with abnormal scalp sensations, with some improvement seen using pain medication and physical therapy.

African American adults and non-White children experience more hair loss episodes than White patients with alopecia areata.

Early treatment with JAK inhibitors leads to better hair regrowth in acute alopecia areata.

Lower postoperative hematocrit levels increase the risk of death within 28 days after coronary artery bypass surgery.

Statins do not help improve alopecia areata.

Statins do not help improve alopecia areata.

Severe COVID-19 increases the risk of hair loss.

5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.

Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.

Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.

Leflunomide may lower alopecia areata risk, while other immunomodulators might increase it.

Androgenetic alopecia doesn't increase the risk of heart-related health issues.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.

Low-dose oral minoxidil is safe for the heart in the short term for hair loss patients.

Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.

Janus Kinase inhibitors are effective and safe for treating alopecia areata, but more research is needed.

Two L-PRP treatments improve hair density in mild to moderate alopecia.